ProCE Banner Activity

TALAPRO-2: Phase III Trial of First-line Talazoparib + Enzalutamide in mCRPC

Capsule Summary
Conference Coverage

Talazoparib plus enzalutamide significantly improved median radiographic PFS vs placebo plus enzalutamide regardless of HRR gene alteration status as first-line therapy for patients with mCRPC.

Released: February 21, 2023

Expiration: February 20, 2024

No longer available for credit.


Provided by

ProCE Banner


This activity is supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.